News >

FDA Grants Daratumumab Combos Breakthrough Designation for Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, Jul 26, 2016

Meletios A. Dimopoulos, MD

Meletios A. Dimopoulos, MD

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy, according to Janssen, which is developing the CD38-targeted antibody with Genmab.

The designation, which will expedite the development and review of the daratumumab regimens, is based on 2 phase III trials. The phase III POLLUX trial demonstrated that combining daratumumab with lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 63% versus lenalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma. In the phase III CASTOR trial, adding daratumumab to bortezomib (Velcade) and dexamethasone reduced the risk of progression or death by 61% in patients with recurrent or refractory multiple myeloma.

“Despite tremendous progress in the past 15 years, multiple myeloma remains a highly complex and difficult disease to treat, with most patients relapsing or becoming resistant to therapy,” POLLUX lead author Meletios A. Dimopoulos, MD, department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Alexandra General Hospital, Athens, Greece, said in a statement. “Daratumumab has already shown pronounced activity as a monotherapy in heavily pretreated patients. This designation underscores the potential of daratumumab in combination with either a proteasome inhibitor or an immunomodulatory agent to provide much-needed benefit to patients with at least one prior therapy.”

The international, open-label POLLUX trial randomized 569 patients with relapsed/refractory multiple myeloma to daratumumab combined with lenalidomide/dexamethasone (n = 286) or lenalidomide plus dexamethasone alone (n = 283). Daratumumab was dosed at 16 mg/kg IV once weekly during cycles 1 and 2, every 2 weeks during cycles 3 to 6, and once only (on day 1) of cycles 7 onward. Oral lenalidomide was administered at 25 mg daily for the first 3 weeks of each cycle and dexamethasone was dosed at 40 mg weekly (20 mg weekly in patients older than 75 or with a BMI <8.5). Treatment cycles for both study arms were 28 days. Patients were treated until progression or unacceptable toxicity.

The median patient age was 65 years. The median number of of prior treatment lines was 1, with 19% of patients having received ≥3 lines of therapy. Eighty-six percent of patients had received a proteasome inhibitor; 55% had been treated with an immunomodulatory agent (IMiD), including 18% with lenalidomide; and 44% had previously receiving both a proteasome inhibitor and an IMiD. Across the study population, 27% of patients were refractory to their most recent treatment and 18% were refractory to a proteasome inhibitor; however, no patients were refractory to lenalidomide.

The primary endpoint of the study was progression-free survival (PFS), with secondary outcome measures including time to progression, overall response rate (ORR), overall survival, and very good partial response (VGPR). At a preplanned interim analysis in May 2016, the study was unblinded after an independent panel determined the trial met its primary endpoint of improved PFS. Patients in the control arm were allowed to receive daratumumab at progression.

At a median follow-up of 13.5 months, the median PFS was not yet reached in the daratumumab arm versus 18.4 months with lenalidomide/dexamethasone alone (HR, 0.37; 95% CI, 0.27-0.52; P <.0001). The ORR was 93% versus 76%, respectively, P <.0001. The VGPR or better rate was 76% with daratumumab versus 44% in the control arm (P <.0001) and the compete response rates were 43% and 19%, respectively (P <.0001).

The safety profile was consistent with previously report adverse events (AEs) for single-agent daratumumab and the combination of lenalidomide and dexamethasone. The most common all-grade AEs included neutropenia (59% with the daratumumab triplet vs 43% in the control arm), diarrhea (43% vs 25%), fatigue (35% vs 28%), upper respiratory tract infection (32% vs 21%), anemia (31% vs 35%), constipation (29% vs 25%), cough (29% vs 13%), thrombocytopenia (27% each), and muscle spasms (26% vs 19%).

Infusion reactions related to daratumumab were reported in 48% of patients and were mostly grade 1/2, with 5% experiencing grade 3. Ninety-two percent of these reactions occurred during the initial infusion.

The most common grade 3/4 AEs were neutropenia (52% in the daratumumab arm vs 37% in the control arm), thrombocytopenia (13% vs 14%), and anemia (12% vs 20%). Grade 3/4 infections occurred in 28% of patients receiving daratumumab compared with 23% of patients in the control arm. The most common grade 3/4 infection was pneumonia, which occurred in 8% of patients in each arm. Discontinuation rates due to AEs occurred in 7% and 8% of patients in the 2 arms, respectively.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication